SMTL ID : 4tt7.1

Crystal structure of human ALK with a covalent modification

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.10 Å

Oligo State

monomer

Ligands

2 x COM: 1-THIOETHANESULFONIC ACID(Non-covalent)

COM.1: 4 residues within 4Å: Chain A: R.138, C.142, Q.145, L.287 1 PLIP interactions: 1 interactions with chain A Salt bridges: A:R.138 COM.2: 3 residues within 4Å: Chain A: G.35, C.63, D.67 2 PLIP interactions: 2 interactions with chain A Hydrogen bonds: A:G.35, A:G.35

3 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)

EDO.3: 5 residues within 4Å: Chain A: F.152, I.153, R.155, A.181, Y.185 2 PLIP interactions: 2 interactions with chain A Hydrogen bonds: A:I.153, A:Y.185 EDO.4: 5 residues within 4Å: Chain A: W.227, P.238, M.255, D.256, P.257 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:D.256 EDO.5: 5 residues within 4Å: Chain A: I.78, S.79, F.81, R.88, C.89 4 PLIP interactions: 4 interactions with chain A Hydrogen bonds: A:I.78, A:R.88, A:C.89 Water bridges: A:H.83

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Parker, A.R. et al., Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787. Onco Targets Ther (2015)

Release Date

2015-02-11

Peptides

ALK tyrosine kinase receptor: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

ALK tyrosine kinase receptor